<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p154" style="overflow: hidden; position: relative; background-color: white; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_154{left:119px;bottom:1134px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2_154{left:799px;bottom:1132px;letter-spacing:-0.08px;}
#t3_154{left:141px;bottom:1081px;letter-spacing:0.14px;word-spacing:-0.28px;}
#t4_154{left:162px;bottom:1046px;letter-spacing:0.05px;}
#t5_154{left:217px;bottom:1046px;letter-spacing:0.07px;word-spacing:-0.49px;}
#t6_154{left:162px;bottom:1029px;letter-spacing:0.11px;word-spacing:0.29px;}
#t7_154{left:162px;bottom:1011px;letter-spacing:0.11px;word-spacing:-0.05px;}
#t8_154{left:162px;bottom:962px;letter-spacing:0.12px;}
#t9_154{left:252px;bottom:962px;letter-spacing:0.11px;word-spacing:0.41px;}
#ta_154{left:162px;bottom:945px;letter-spacing:0.11px;word-spacing:0.05px;}
#tb_154{left:162px;bottom:927px;letter-spacing:0.12px;word-spacing:2.95px;}
#tc_154{left:162px;bottom:909px;letter-spacing:0.11px;word-spacing:-0.04px;}
#td_154{left:162px;bottom:892px;letter-spacing:0.12px;word-spacing:0.96px;}
#te_154{left:320px;bottom:892px;letter-spacing:0.12px;word-spacing:0.96px;}
#tf_154{left:162px;bottom:874px;letter-spacing:0.11px;word-spacing:-0.31px;}
#tg_154{left:162px;bottom:857px;letter-spacing:0.11px;word-spacing:-0.49px;}
#th_154{left:162px;bottom:839px;letter-spacing:0.11px;word-spacing:0.03px;}
#ti_154{left:162px;bottom:821px;letter-spacing:0.1px;}
#tj_154{left:219px;bottom:821px;letter-spacing:0.11px;word-spacing:0.1px;}
#tk_154{left:162px;bottom:804px;letter-spacing:0.11px;word-spacing:1.26px;}
#tl_154{left:162px;bottom:787px;letter-spacing:0.11px;word-spacing:0.81px;}
#tm_154{left:162px;bottom:769px;letter-spacing:0.08px;word-spacing:0.67px;}
#tn_154{left:162px;bottom:751px;letter-spacing:0.11px;word-spacing:2.86px;}
#to_154{left:162px;bottom:734px;letter-spacing:0.09px;}
#tp_154{left:162px;bottom:716px;letter-spacing:0.11px;}
#tq_154{left:239px;bottom:716px;letter-spacing:0.11px;word-spacing:-0.49px;}
#tr_154{left:162px;bottom:699px;letter-spacing:0.11px;word-spacing:-0.28px;}
#ts_154{left:162px;bottom:681px;letter-spacing:0.1px;word-spacing:-0.53px;}
#tt_154{left:162px;bottom:663px;letter-spacing:0.11px;word-spacing:0.15px;}
#tu_154{left:162px;bottom:646px;letter-spacing:0.1px;}
#tv_154{left:162px;bottom:628px;letter-spacing:0.13px;}
#tw_154{left:300px;bottom:628px;letter-spacing:0.11px;word-spacing:1.97px;}
#tx_154{left:162px;bottom:611px;letter-spacing:0.11px;word-spacing:0.03px;}
#ty_154{left:141px;bottom:554px;letter-spacing:0.14px;word-spacing:-0.94px;}
#tz_154{left:162px;bottom:533px;letter-spacing:0.14px;}
#t10_154{left:162px;bottom:498px;letter-spacing:0.13px;word-spacing:0.02px;}
#t11_154{left:279px;bottom:498px;letter-spacing:0.1px;word-spacing:0.03px;}
#t12_154{left:162px;bottom:481px;letter-spacing:0.11px;word-spacing:0.03px;}
#t13_154{left:162px;bottom:446px;letter-spacing:0.14px;}
#t14_154{left:252px;bottom:446px;letter-spacing:0.11px;word-spacing:0.41px;}
#t15_154{left:162px;bottom:428px;letter-spacing:0.11px;word-spacing:2.04px;}
#t16_154{left:162px;bottom:410px;letter-spacing:0.11px;word-spacing:1.07px;}
#t17_154{left:162px;bottom:393px;letter-spacing:0.09px;}
#t18_154{left:162px;bottom:375px;letter-spacing:0.12px;word-spacing:-0.36px;}
#t19_154{left:316px;bottom:375px;letter-spacing:0.1px;word-spacing:-0.37px;}
#t1a_154{left:162px;bottom:358px;letter-spacing:0.11px;word-spacing:1.01px;}
#t1b_154{left:162px;bottom:340px;letter-spacing:0.11px;word-spacing:0.99px;}
#t1c_154{left:162px;bottom:323px;letter-spacing:0.11px;word-spacing:0.03px;}
#t1d_154{left:162px;bottom:305px;letter-spacing:0.1px;}
#t1e_154{left:218px;bottom:305px;letter-spacing:0.1px;word-spacing:-0.67px;}
#t1f_154{left:162px;bottom:288px;letter-spacing:0.11px;word-spacing:-0.64px;}
#t1g_154{left:162px;bottom:270px;letter-spacing:0.11px;word-spacing:0.81px;}
#t1h_154{left:162px;bottom:252px;letter-spacing:0.11px;word-spacing:-0.28px;}
#t1i_154{left:162px;bottom:235px;letter-spacing:0.11px;word-spacing:1.88px;}
#t1j_154{left:162px;bottom:217px;letter-spacing:0.09px;}
#t1k_154{left:162px;bottom:200px;letter-spacing:0.11px;}
#t1l_154{left:242px;bottom:200px;letter-spacing:0.12px;word-spacing:1.39px;}
#t1m_154{left:162px;bottom:182px;letter-spacing:0.11px;word-spacing:0.04px;}
#t1n_154{left:162px;bottom:165px;letter-spacing:0.11px;word-spacing:0.81px;}
#t1o_154{left:162px;bottom:147px;letter-spacing:0.12px;word-spacing:3.19px;}
#t1p_154{left:162px;bottom:129px;letter-spacing:0.1px;word-spacing:0.03px;}
#t1q_154{left:162px;bottom:112px;letter-spacing:0.13px;}
#t1r_154{left:293px;bottom:112px;letter-spacing:0.12px;word-spacing:0.79px;}
#t1s_154{left:162px;bottom:94px;letter-spacing:0.11px;word-spacing:0.77px;}
#t1t_154{left:162px;bottom:77px;letter-spacing:0.11px;word-spacing:0.03px;}

.s0_154{font-size:15px;font-family:TimesNewRomanPSMT_6e;color:#000;}
.s1_154{font-size:17px;font-family:Calibri_7k;color:#000;}
.s2_154{font-size:18px;font-family:TimesNewRomanPS-BoldMT_7w;color:#000;}
.s3_154{font-size:15px;font-family:TimesNewRomanPS-BoldMT_7s;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts154" type="text/css" >

@font-face {
	font-family: Calibri_7k;
	src: url("fonts/Calibri_7k.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7s;
	src: url("fonts/TimesNewRomanPS-BoldMT_7s.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPS-BoldMT_7w;
	src: url("fonts/TimesNewRomanPS-BoldMT_7w.woff") format("woff");
}

@font-face {
	font-family: TimesNewRomanPSMT_6e;
	src: url("fonts/TimesNewRomanPSMT_6e.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg154Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg154" style="-webkit-user-select: none;"><object width="935" height="1210" data="154/154.svg" type="image/svg+xml" id="pdf154" style="width:935px; height:1210px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_154" class="t s0_154">Brain: Chemistry to Cognition </span><span id="t2_154" class="t s1_154">146 </span>
<span id="t3_154" class="t s2_154">P118: Analysis of Tmem119 for its possible involvement in microglia functions </span>
<span id="t4_154" class="t s3_154">Shweta, </span><span id="t5_154" class="t s0_154">Himanshi Yadav, Shashank Kumar Maurya </span>
<span id="t6_154" class="t s0_154">Biochemistry and Molecular Biology Laboratory, Department of Zoology, Faculty ofScience, University of </span>
<span id="t7_154" class="t s0_154">Delhi, Delhi-110007 </span>
<span id="t8_154" class="t s3_154">Background: </span><span id="t9_154" class="t s0_154">Microglia plays an important role in the regulation of neuroinflammation-drivenneurological </span>
<span id="ta_154" class="t s0_154">disorders. Recently, Tmem119 has been identified as a marker of adult microgliawhose expression has been </span>
<span id="tb_154" class="t s0_154">shown to alter during neuroinflammation. However, analysis of the Tmem119 protein and its possible </span>
<span id="tc_154" class="t s0_154">involvement in neuroinflammation need to be deciphered. </span>
<span id="td_154" class="t s3_154">Material and Methods: </span><span id="te_154" class="t s0_154">RT-PCR and western blotting were performed in an LPS-induced mice model of </span>
<span id="tf_154" class="t s0_154">neuroinflammation to study the expression pattern of Tmem119. Physio- chemical properties, secondary and </span>
<span id="tg_154" class="t s0_154">tertiary structures were predicted using ExPASy ProtParam, PSIPRED and Swiss-Prot, respectively. Protein- </span>
<span id="th_154" class="t s0_154">protein interaction and signalling pathways were predicted using STRING. </span>
<span id="ti_154" class="t s3_154">Results: </span><span id="tj_154" class="t s0_154">The expression of Tmem119 at both transcript and protein levels was observed to increase in LPS- </span>
<span id="tk_154" class="t s0_154">induced mice as compared to the control. Regarding physiochemical properties, the number of negatively </span>
<span id="tl_154" class="t s0_154">charged residues was double the number of positively charges residues. The instability index and aliphatic </span>
<span id="tm_154" class="t s0_154">index were very high. The GRAVY indexis negative. The secondary structure showed a large portion of Î±- </span>
<span id="tn_154" class="t s0_154">helices. Tmem119 is predicted to interact with proteins of microglia involved in various physiological </span>
<span id="to_154" class="t s0_154">functions. </span>
<span id="tp_154" class="t s3_154">Discussion: </span><span id="tq_154" class="t s0_154">The results of the present study demonstrated an increase in Tmem119 expressionin LPS-treated </span>
<span id="tr_154" class="t s0_154">mice. Tmem119 is a single-pass transmembrane protein of 280 amino acids found in microglia. It is unstable </span>
<span id="ts_154" class="t s0_154">in ex-vivo conditions and shows high thermostability due to the presence of a high number of aliphatic amino </span>
<span id="tt_154" class="t s0_154">acids. Extracellular and intracellular domainsare hydrophilic and transmembrane is hydrophobic. Tmem119 </span>
<span id="tu_154" class="t s0_154">interaction with microglial proteins using STRING predicts its role in microglial cellular processes. </span>
<span id="tv_154" class="t s3_154">Acknowledgements: </span><span id="tw_154" class="t s0_154">Financial support of the Institution of Eminence, University of Delhi (IoE, DU) is </span>
<span id="tx_154" class="t s0_154">gratefully acknowledged. </span>
<span id="ty_154" class="t s2_154">P119: Development of small molecules as potential mutant SOD-1 aggregation inhibitors </span>
<span id="tz_154" class="t s2_154">for the amelioration of Amyotrophic lateral sclerosis </span>
<span id="t10_154" class="t s3_154">Siddharth Gusain</span><span id="t11_154" class="t s0_154">, Manisha Tiwari </span>
<span id="t12_154" class="t s0_154">Dr. B. R. Ambedkar Center for Biomedical Research </span>
<span id="t13_154" class="t s3_154">Background: </span><span id="t14_154" class="t s0_154">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss </span>
<span id="t15_154" class="t s0_154">of upper and lower motor neurons. Cu/Zn superoxide dismutase is one of the genes associated with the </span>
<span id="t16_154" class="t s0_154">familial form of the disease (fALS). It is hypothesized that a toxic gain of function in the protein leads to </span>
<span id="t17_154" class="t s0_154">ALS. </span>
<span id="t18_154" class="t s3_154">Material and Methods: </span><span id="t19_154" class="t s0_154">Novel synthesized molecules were tested for their ability to prevent the aggregation </span>
<span id="t1a_154" class="t s0_154">of hSOD1 protein-associated toxicity in Neuro-2a cells overexpressing G85R hSOD1 mutation. Cells pre- </span>
<span id="t1b_154" class="t s0_154">treated with the small molecules were further treated by MG-132 and effects were analyzed by evaluating </span>
<span id="t1c_154" class="t s0_154">cell death, ROS generation, Apoptosis and Mitochondrial membrane potential. </span>
<span id="t1d_154" class="t s3_154">Results: </span><span id="t1e_154" class="t s0_154">Small molecules SG-9 and SG-10 displayed very low toxicity to the transfected cells. Both the small </span>
<span id="t1f_154" class="t s0_154">molecules considerably prevented cell death as compared to the MG-132 treated cells. These small molecules </span>
<span id="t1g_154" class="t s0_154">were able to significantly reduce oxidative stress associated with the aggregation of mutant SOD1 protein. </span>
<span id="t1h_154" class="t s0_154">The molecules were also able to prevent apoptosis in the cells which was analyzed by Annexin V-PI staining </span>
<span id="t1i_154" class="t s0_154">and western blotting. These molecules were also able to restore mitochondrial membrane potential upon </span>
<span id="t1j_154" class="t s0_154">treatment. </span>
<span id="t1k_154" class="t s3_154">Discussion: </span><span id="t1l_154" class="t s0_154">Currently, there are only two FDA-approved drugs; Riluzole and Edaravone, which are non- </span>
<span id="t1m_154" class="t s0_154">curative and marginally slow disease progression by a few months. Our study provides small molecules that </span>
<span id="t1n_154" class="t s0_154">can be further used for lead optimization and can provide targeted benefits and better therapeutic potential </span>
<span id="t1o_154" class="t s0_154">for SOD1-associated ALS. Our compounds were able to ameliorate the effects associated with SOD1 </span>
<span id="t1p_154" class="t s0_154">aggregation in a transfected N2a cell line model. </span>
<span id="t1q_154" class="t s3_154">Acknowledgement: </span><span id="t1r_154" class="t s0_154">S.G. would like to thank DU-Non-NET and ICMR-SRF for providing the fellowship. </span>
<span id="t1s_154" class="t s0_154">M.T. would like to acknowledge the Institute of Eminence Grant,2021-22 and Maintenance Grant, ACBR, </span>
<span id="t1t_154" class="t s0_154">DU for providing the financial support to conduct the study. </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
